You just read:

REGENXBIO Receives Rare Pediatric Disease Designation for RGX-181 Gene Therapy for the Treatment of CLN2 Form of Batten Disease

News provided by

REGENXBIO Inc.

Jan 31, 2019, 07:00 ET